Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Vural Taner
dc.contributor.authorSuleymanlar, Gultekin
dc.contributor.authorKoksoy, Sadi
dc.contributor.authorUlger, Burak Veli
dc.contributor.authorOzdem, Sebahat
dc.contributor.authorAkbas, Halide
dc.contributor.authorAkkaya, Bahar
dc.date.accessioned2024-04-24T17:20:29Z
dc.date.available2024-04-24T17:20:29Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: The aim of our study was to determine the effectiveness of immunoglobulin, rituximab and plasmapheresis in renal transplant patients with antibody mediated rejection (AMR). Patients and Methods: Fourteen renal transplant patients with AMR were included in this study. The mean age of the patients was 33.9 +/- 10.3years and 10 (71.4%) of them were male. Lymphocyte cross match was negative for all patients and 10 (71.4%) of them were living donor transplants. Six patients were administered tacrolimus, three patients cyclosporine, two patients everolimus, and three patients sirolimus for immunosuppression. The patients with AMR were administered IVIG, rituximab and plasmapheresis. Results: Patient survival rate was 100%, graft survival rate after AMR was 50% in the first year and 33% in the 2nd and third years. AMR developed 31.9 +/- 25.9 months after transplantation. Seven (50%) patients lost their grafts. Delayed graft function was observed in 28.6%, chronic allograft dysfunction in 78.5%, diabetes after transplantation in 14.3%, and cytomegalovirus infection in 7.1% of the patients. At the last follow-up, the mean blood creatinine was 3.1 +/- 1.4, the mean proteinuria was 2300 (1300-3300) mg/day and the mean GFR was 34.5 +/- 17.6ml/min. C4d was positive in peritubullar capillaries in all patients, while neutrophil accumulation in peritubular and glomerular capillaries was observed in 8 patients. Chronic allograft vasculopathy was observed in 12 patients. Conclusion: AMR leads to progressive loss of renal function and has low graft survival. More effective treatment alternatives are needed for this clinical issue.en_US
dc.identifier.doi10.3109/08941939.2016.1154626
dc.identifier.endpage288en_US
dc.identifier.issn0894-1939
dc.identifier.issn1521-0553
dc.identifier.issue5en_US
dc.identifier.pmid27002854
dc.identifier.scopus2-s2.0-84961390658
dc.identifier.scopusqualityQ1
dc.identifier.startpage282en_US
dc.identifier.urihttps://doi.org/10.3109/08941939.2016.1154626
dc.identifier.urihttps://hdl.handle.net/11468/19080
dc.identifier.volume29en_US
dc.identifier.wosWOS:000384017200006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofJournal of Investigative Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntibody Mediated Rejectionen_US
dc.subjectRenal Transplantationen_US
dc.subjectImmunoglobulinen_US
dc.subjectRituximaben_US
dc.subjectPlasmapheresisen_US
dc.titleTherapy Modalities for Antibody Mediated Rejection in Renal Transplant Patientsen_US
dc.titleTherapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu